44 research outputs found
Recommended from our members
Nitrogen alters carbon dynamics during early succession in boreal forest
Boreal forests are an important source of wood products, and fertilizers could be used to improve forest yields, especially in nutrient poor regions of the boreal zone. With climate change, fire frequencies may increase, resulting in a larger fraction of the boreal landscape present in early-successional stages. Since most fertilization studies have focused on mature boreal forests, the response of burned boreal ecosystems to increased nutrient availability is unclear. Therefore, we used a nitrogen (N) fertilization experiment to test how C cycling in a recently-burned boreal ecosystem would respond to increased N availability. We hypothesized that fertilization would increase rates of decomposition, soil respiration, and the activity of extracellular enzymes involved in C cycling, thereby reducing soil C stocks. In line with our hypothesis, litter mass loss increased significantly and activities of cellulose- and chitin-degrading enzymes increased by 45–61% with N addition. We also observed a significant decline in C concentrations in the organic soil horizon from 19.5 ± 0.7% to 13.5 ± 0.6%, and there was a trend toward lower total soil C stocks in the fertilized plots. Contrary to our hypothesis, mean soil respiration over three growing seasons declined by 31% from 78.3 ± 6.5 mg CO2–C m−2 h−1 to 54.4 ± 4.1 mg CO2–C m−2 h−1. These changes occurred despite a 2.5-fold increase in aboveground net primary productivity with N, and were accompanied by significant shifts in the structure of the fungal community, which was dominated by Ascomycota. Our results show that the C cycle in early-successional boreal ecosystems is highly responsive to N addition. Fertilization results in an initial loss of soil C followed by depletion of soil C substrates and development of a distinct and active fungal community. Total microbial biomass declines and respiration rates do not keep pace with plant inputs. These patterns suggest that N fertilization could transiently reduce but then increase ecosystem C storage in boreal regions experiencing more frequent fires
A fast extraction-free isothermal LAMP assay for detection of SARS-CoV-2 with potential use in resource-limited settings
BACKGROUND: To retain the spread of SARS-CoV-2, fast, sensitive and cost-effective testing is essential, particularly in resource limited settings (RLS). Current standard nucleic acid-based RT-PCR assays, although highly sensitive and specific, require transportation of samples to specialised laboratories, trained staff and expensive reagents. The latter are often not readily available in low- and middle-income countries and this may significantly impact on the successful disease management in these settings. Various studies have suggested a SARS-CoV-2 loop mediated isothermal amplification (LAMP) assay as an alternative method to RT-PCR. METHODS: Four previously published primer pairs were used for detection of SARS-CoV-2 in the LAMP assay. To determine optimal conditions, different temperatures, sample input and incubation times were tested. Ninety-three extracted RNA samples from St. George's Hospital, London, 10 non-extracted nasopharyngeal swab samples from Great Ormond Street Hospital for Children, London, and 92 non-extracted samples from Queen Elisabeth Central Hospital (QECH), Malawi, which have previously been tested for SARS-Cov-2 by quantitative reverse-transcription RealTime PCR (qRT-PCR), were analysed in the LAMP assay. RESULTS: In this study we report the optimisation of an extraction-free colourimetric SARS-CoV-2 LAMP assay and demonstrated that a lower limit of detection (LOD) between 10 and 100 copies/µL of SARS-CoV-2 could be readily detected by a colour change of the reaction within as little as 30 min. We further show that this assay could be quickly established in Malawi, as no expensive equipment is necessary. We tested 92 clinical samples from QECH and showed the sensitivity and specificity of the assay to be 86.7% and 98.4%, respectively. Some viral transport media, used routinely to stabilise RNA in clinical samples during transportation, caused a non-specific colour-change in the LAMP reaction and therefore we suggest collecting samples in phosphate buffered saline (which did not affect the colour) as the assay allows immediate sample analysis on-site. CONCLUSION: SARS-CoV-2 LAMP is a cheap and reliable assay that can be readily employed in RLS to improve disease monitoring and management
Modeling Collective Cell Behavior in Cancer: Perspectives From an Interdisciplinary Conversation
Collective cell behavior contributes to all stages of cancer progression. Understanding how collective behavior emerges through cell-cell interactions and decision-making will advance our understanding of cancer biology and provide new therapeutic approaches. Here, we summarize an interdisciplinary discussion on multicellular behavior in cancer, draw lessons from other scientific disciplines, and identify future directions
Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome
Autosomal dominant hyper-IgE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations. Patients suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal abnormalities. We report 12 patients from 8 unrelated kindreds with AD-HIES due to DN IL6ST mutations. We identified seven different truncating mutations, one of which was recurrent. The mutant alleles encode GP130 receptors bearing the transmembrane domain but lacking both the recycling motif and all four STAT3-recruiting tyrosine residues. Upon overexpression, the mutant proteins accumulate at the cell surface and are loss of function and DN for cellular responses to IL-6, IL-11, LIF, and OSM. Moreover, the patients’ heterozygous leukocytes and fibroblasts respond poorly to IL-6 and IL-11. Consistently, patients with STAT3 and IL6ST mutations display infectious and allergic manifestations of IL-6R deficiency, and some of the skeletal abnormalities of IL-11R deficiency. DN STAT3 and IL6ST mutations thus appear to underlie clinical phenocopies through impairment of the IL-6 and IL-11 response pathways
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Background:
Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
Methods:
We nested a two-period, fixed-order pharmacokinetic substudy within the open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres in South Africa, Uganda, and Zimbabwe. Children (aged 4 weeks to <18 years) with HIV-associated TB who were receiving rifampicin and twice-daily dolutegravir were eligible for inclusion. We did a 12-h pharmacokinetic profile on rifampicin and twice-daily dolutegravir and a 24-h profile on once-daily dolutegravir. Geometric mean ratios for trough plasma concentration (Ctrough), area under the plasma concentration time curve from 0 h to 24 h after dosing (AUC0–24 h), and maximum plasma concentration (Cmax) were used to compare dolutegravir concentrations between substudy days. We assessed rifampicin Cmax on the first substudy day. All children within ODYSSEY with HIV-associated TB who received rifampicin and twice-daily dolutegravir were included in the safety analysis. We described adverse events reported from starting twice-daily dolutegravir to 30 days after returning to once-daily dolutegravir. This trial is registered with ClinicalTrials.gov (NCT02259127), EudraCT (2014–002632-14), and the ISRCTN registry (ISRCTN91737921).
Findings:
Between Sept 20, 2016, and June 28, 2021, 37 children with HIV-associated TB (median age 11·9 years [range 0·4–17·6], 19 [51%] were female and 18 [49%] were male, 36 [97%] in Africa and one [3%] in Thailand) received rifampicin with twice-daily dolutegravir and were included in the safety analysis. 20 (54%) of 37 children enrolled in the pharmacokinetic substudy, 14 of whom contributed at least one evaluable pharmacokinetic curve for dolutegravir, including 12 who had within-participant comparisons. Geometric mean ratios for rifampicin and twice-daily dolutegravir versus once-daily dolutegravir were 1·51 (90% CI 1·08–2·11) for Ctrough, 1·23 (0·99–1·53) for AUC0–24 h, and 0·94 (0·76–1·16) for Cmax. Individual dolutegravir Ctrough concentrations were higher than the 90% effective concentration (ie, 0·32 mg/L) in all children receiving rifampicin and twice-daily dolutegravir. Of 18 children with evaluable rifampicin concentrations, 15 (83%) had a Cmax of less than the optimal target concentration of 8 mg/L. Rifampicin geometric mean Cmax was 5·1 mg/L (coefficient of variation 71%). During a median follow-up of 31 weeks (IQR 30–40), 15 grade 3 or higher adverse events occurred among 11 (30%) of 37 children, ten serious adverse events occurred among eight (22%) children, including two deaths (one tuberculosis-related death, one death due to traumatic injury); no adverse events, including deaths, were considered related to dolutegravir.
Interpretation:
Twice-daily dolutegravir was shown to be safe and sufficient to overcome the rifampicin enzyme-inducing effect in children, and could provide a practical ART option for children with HIV-associated TB
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus alternative antiretroviral therapy. METHODS: This is a secondary analysis of ODYSSEY, an open-label, multicentre, randomised, non-inferiority trial, in which adolescents and children initiating first-line or second-line antiretroviral therapy were randomly assigned 1:1 to dolutegravir-based treatment or standard-of-care treatment. We assessed neuropsychiatric adverse events (reported by clinicians) and responses to the mood and sleep questionnaires (reported by the participant or their carer) in both groups. We compared the proportions of patients with neuropsychiatric adverse events (neurological, psychiatric, and total), time to first neuropsychiatric adverse event, and participant-reported responses to questionnaires capturing issues with mood, suicidal thoughts, and sleep problems. FINDINGS: Between Sept 20, 2016, and June 22, 2018, 707 participants were enrolled, of whom 345 (49%) were female and 362 (51%) were male, and 623 (88%) were Black-African. Of 707 participants, 350 (50%) were randomly assigned to dolutegravir-based antiretroviral therapy and 357 (50%) to non-dolutegravir-based standard-of-care. 311 (44%) of 707 participants started first-line antiretroviral therapy (ODYSSEY-A; 145 [92%] of 157 participants had efavirenz-based therapy in the standard-of-care group), and 396 (56%) of 707 started second-line therapy (ODYSSEY-B; 195 [98%] of 200 had protease inhibitor-based therapy in the standard-of-care group). During follow-up (median 142 weeks, IQR 124–159), 23 participants had 31 neuropsychiatric adverse events (15 in the dolutegravir group and eight in the standard-of-care group; difference in proportion of participants with ≥1 event p=0·13). 11 participants had one or more neurological events (six and five; p=0·74) and 14 participants had one or more psychiatric events (ten and four; p=0·097). Among 14 participants with psychiatric events, eight participants in the dolutegravir group and four in standard-of-care group had suicidal ideation or behaviour. More participants in the dolutegravir group than the standard-of-care group reported symptoms of self-harm (eight vs one; p=0·025), life not worth living (17 vs five; p=0·0091), or suicidal thoughts (13 vs none; p=0·0006) at one or more follow-up visits. Most reports were transient. There were no differences by treatment group in low mood or feeling sad, problems concentrating, feeling worried or feeling angry or aggressive, sleep problems, or sleep quality. INTERPRETATION: The numbers of neuropsychiatric adverse events and reported neuropsychiatric symptoms were low. However, numerically more participants had psychiatric events and reported suicidality ideation in the dolutegravir group than the standard-of-care group. These differences should be interpreted with caution in an open-label trial. Clinicians and policy makers should consider including suicidality screening of children or adolescents receiving dolutegravir
Recommended from our members
Nitrogen alters carbon dynamics during early succession in boreal forest
Boreal forests are an important source of wood products, and fertilizers could be used to improve forest yields, especially in nutrient poor regions of the boreal zone. With climate change, fire frequencies may increase, resulting in a larger fraction of the boreal landscape present in early-successional stages. Since most fertilization studies have focused on mature boreal forests, the response of burned boreal ecosystems to increased nutrient availability is unclear. Therefore, we used a nitrogen (N) fertilization experiment to test how C cycling in a recently-burned boreal ecosystem would respond to increased N availability. We hypothesized that fertilization would increase rates of decomposition, soil respiration, and the activity of extracellular enzymes involved in C cycling, thereby reducing soil C stocks. In line with our hypothesis, litter mass loss increased significantly and activities of cellulose- and chitin-degrading enzymes increased by 45–61% with N addition. We also observed a significant decline in C concentrations in the organic soil horizon from 19.5 ± 0.7% to 13.5 ± 0.6%, and there was a trend toward lower total soil C stocks in the fertilized plots. Contrary to our hypothesis, mean soil respiration over three growing seasons declined by 31% from 78.3 ± 6.5 mg CO2–C m−2 h−1 to 54.4 ± 4.1 mg CO2–C m−2 h−1. These changes occurred despite a 2.5-fold increase in aboveground net primary productivity with N, and were accompanied by significant shifts in the structure of the fungal community, which was dominated by Ascomycota. Our results show that the C cycle in early-successional boreal ecosystems is highly responsive to N addition. Fertilization results in an initial loss of soil C followed by depletion of soil C substrates and development of a distinct and active fungal community. Total microbial biomass declines and respiration rates do not keep pace with plant inputs. These patterns suggest that N fertilization could transiently reduce but then increase ecosystem C storage in boreal regions experiencing more frequent fires
Transforming ecological science at primarily undergraduate institutions through collaborative networks
Ecologists at primarily undergraduate institutions (PUIs) are well positioned to form collaborative networks and make transformative contributions to the study and teaching of ecology. The spatial and temporal complexity of ecological phenomena rewards a collaborative research approach. A network of PUI ecologists can incorporate closely supervised data collection into undergraduate courses, thereby generating data across spatial gradients to answer crucial questions. These data can offer unprecedented insight into fine-and large-scale spatial processes for publications, resource management, and policy decisions. Undergraduate students benefit from the collaborative research experience as they gain experiential learning in team building, project design, implementation, data collection, and analysis. With appropriate funding, collaborative networks make excellent use of the intellectual and experiential capital of PUI faculty for the benefit of science, pedagogy, and society. © 2011 by American Institute of Biological Sciences. All rights reserved